A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

Kodiak Sciences shares tripled in one session after its eye-drug candidate cleared a pivotal trial, a major clinical validation event for the pre-revenue biotech. However, the company remains cash-burning with no revenue, and the likelihood of an equity offering creates substantial dilution risk for investors considering chasing the rally.